Rekombinanter CDK4 Antikörper (N-Term)

Produktnummer ABIN7879591

Der Kaninchen Monoklonal anti-CDK4 Antikörper (Klon CDK4-8351R) (ABIN7879591) detektiert spezifisch CDK4 in IHC (p). Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter CDK4 Antikörper (N-Term) (ABIN7879591)

Target: CDK4 (Cyclin-Dependent Kinase 4 (CDK4))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser CDK4 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: CDK4-8351R

Produktdetails anti-CDK4 Antikörper

Bindungsspezifität: N-Term

Verwendungszweck: Recombinant CDK4 Antibody (azide and preservative free)

Aufreinigung: Protein A/G affinity

Immunogen: A recombinant fragment corresponding to the N-terminal of human CDK4 protein was used as the immunogen for the recombinant CDK4 antibody.

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the recombinant CDK4 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Aliquot the recombinant CDK4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu CDK4

Target: CDK4 (Cyclin-Dependent Kinase 4 (CDK4))

Andere Bezeichnung: CDK4

Hintergrund: Cyclin-dependent kinase-4 (CDK4) is a protein-serine kinase involved in the cell cycle. It is essential for the G1- to S-phase transition during the cell cycle and its expression is primarily controlled at the transcriptional level. CCND1- CDK4 axis is not only critical in glial tumor cells but also in stromal-derived cells in the surrounding tumor microenvironment that are vital to sustain tumor outgrowth. CDK4 is highly expressed in highly differentiated and dedifferentiated liposarcomas, but rarely expressed in other benign liposarcomas and other sarcomas. CDK4 and MDM2 combined to differentiate between highly differentiated liposarcoma (+), dedifferentiated liposarcoma (+) and myxoid liposarcoma, pleomorphic liposarcoma, spindle lipoma, pleomorphic lipoma and other high-grade sarcomas.

UniProt: P11802

Pathways: Zellzyklus, Mitotic G1-G1/S Phases, Regulation of Cell Size